<unk>  is defined as a platelet count of <100,000 cell/mm3. The morbidity and mortality associated with percutaneous coronary intervention (PCI) has substantially improved given recent advances in devices and pharmacotherapy. Increased utilization of antiplatelet and antithrombin therapies has been associated with fewer postprocedure ischemic complications. Despite these benefits, there is also an increased risk of bleeding and hematologic complications. One such hematologic complication is<unk> . Both antiplatelet and antithrombin agents have been associated with a heightened risk of developing<unk> . Furthermore, patients with pre-PCI<unk>  are at an increased risk for mortality and hemorrhage as compared to patients without<unk> .
PCI complications: thrombocytopenia
PCI complications: renal failure
PCI complications: dissection
PCI complications: coronary vasospasm
PCI complications: slow flow
PCI complications: peri procedure bleeding
PCI complications: vessel perforation
PCI complications: distal embolization